p150 overexpression in gastric carcinoma: The association with p53, apoptosis and cell proliferation

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 393-398

  Chen, Gaoping ^a   Burger, Max M ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Apoptosis; Early marker for gastric carcinoma; Ki 67; p150 overexpression; p53

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIGOXIGENIN; DNA NUCLEOTIDYLEXOTRANSFERASE; KI 67 ANTIGEN; P150 PROTEIN; PROTEIN DERIVATIVE; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; METASTASIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; STATISTICAL ANALYSIS; STOMACH CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6344237621     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20443     Document Type: Article

References (40)

1. Bachmann F, Baenziger R, Burger MM. Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res 1997;57:988-94.
2. Lin L, Holbro T, Alonso G, Gerosa D, Burger MM. Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7. J Cell Biochem 2001;80:483-90.
3. Dellas A, Torhorst J, Bachmann F, Baenziger R, Schultheiss E, Burger MM. Expression of p150 in cervical neoplasia and its potential prognostic value for survival. Cancer 1998;83:1376-83.
4. Chen G, Burger MM. p150 expression and its prognostic value in squamous cell carcinoma of esophagus. Int J Cancer (Pred Oncol) 1999;84:95-100.
5. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
6. Meyer HJ, Jaehne J, Pichlmayr R. Strategies in the surgical treatment of gastric carcinoma. Ann Oncol 1994;5(Suppl 3):S33-6.
7. Borchard F. Classification of gastric carcinoma. Hepato-Gastroenterology 1990;37:223-32.
8. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
9. Wright PA, Quirke P, Attanoos R, Williams GT. Molecular pathology of gastric carcinoma: progress and prospects. Hum Pathol 1992;23:848-59.
10. Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Kotoh O, Yoshida T, Sugimura T, Terada M. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 1990;87:5983-7.
11. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996;23:307-19.
12. Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer (Pred Oncol) 1996;69:200-4.
13. UICC. TNM classification of malignant tumors, 4th ed. Berlin: Springer, 1987. 43-6.
14. Watanabe H, Jass JR, Sobin LH. Histological typing of esophageal and gastric tumors. 2nd ed. Springer. Berlin. 1990.
15. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled-antibody (PAP) procedures. J Histochem Cytochem 1981;29:557-80.
16. Mueller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759-65.
17. Lu C, Tanigawa N. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Cancer Res 1997;57:221-4.
18. Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, Wang TH, Chuang SM. Relationship of p53 and c-erbB-2 expression to histopathological features, helicobacter pylori infection and prognosis in gastric cancer. Hepato-Gastroenterology 1997;44:604-9.
19. Evan G. Cancer: a matter of life and cell death. Int J Cancer 1997;71:709-11.
20. Burger MM, Harris C. UICC study group on basic and clinical cancer research: apoptosis in normal and tumor cells. Int J Cancer 1995;60:590-2.
21. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
22. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
23. Marx J. Cell death studies yield cancer clues. Science 1993;259:760-1.
24. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I. Correlation of apoptosis with tumor cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol 1996;49:134-8.
25. Ohbu M, Saegusa M, Okayasu I. Apoptosis and cellular proliferation in esophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Virch Arch 1995;427:271-6.
26. Kobayashi M, Watanabe H, Ajioka Y, Yoshida M, Hitomi J, Asakura H. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virch Arch 1995;427:27-32.
27. Ikeda M, Shomori K, Endo K, Makino T, Matsuura T, Ito H. Frequent occurrence of apoptosis is an early event in the oncogenesis of human gastric carcinoma. Virch Arch 1998;432:43-7.
28. Shinohara T, Ohshima K, Murayama H, Kikuchi M, Yamashita Y, Shirakusa T. Apoptosis and proliferation in gastric carcinoma: the association with histological type. Histopathology 1996;29:123-9.
29. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
30. Bellamy COC, Malcomson R, Wyllie AH. The roles of p53 in apoptosis and cancer. In: Martin SJ, ed. Apoptosis and cancer. London: Karger Landes Systems, 1997. 116-40.
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
32. Soussi T, Legros Y, Lubin R, Dry K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
33. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
34. Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA, Stern PL. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-12.
35. Gabbert HE, Mueller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
36. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996;32A:215-20.
37. Cattoretti G, Becker MGH, Key G, Duchrow M, Schlueter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
38. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
39. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-7.
40. Ochiai A, Yamauchi Y, Hirohashi S. P53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer (Pred Oncol) 1996;69:28-33.